Announcements Trials
Browse Landscape

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 20Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 447Surgical Procedures, Operative 164Observation 152Drug Therapy 143Radiotherapy 142Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 79Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 67Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 62Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × olverembatinib × Clear all
NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06390306 2025-06-03

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Peking University People's Hospital

Recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡